You searched for Cybin - Page 53 of 61

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders

Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia The company is also developing a clinical trial to address the needs of … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics

Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disorders Tryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders

Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutions The company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomas Tryp has partnered with the University of Florida to conduct a Phase … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders”

QualityStocksNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Releases Corporate Update

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has provided a corporate update regarding its cannabis, functional mushroom and psilocybin business operations. The update notes that, in spite of COVID-19, its Pemberton, British Columbia facility is fully operational … Continue reading “QualityStocksNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Releases Corporate Update”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Is ‘One to Watch’

Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways The company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas) Through its PFN(TM) program, the company is … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Is ‘One to Watch’”

Site Search

Company Search

Search Results for: Cybin